Jacob F. Siegel is an associate in the Firm's Litigation department. Jake represents clients in a wide variety of matters in federal and state courts, including patent, antitrust, and complex commercial disputes. He has represented pharmaceutical companies in patent disputes involving both small molecule drugs and biologics. Jake has also represented clients in a range of other sectors, from manufacturing companies to non-profit organizations.
Successfully represented a major pharmaceutical company in an ANDA action involving challenges to patents covering a combination drug therapy and processes for its manufacture.
Representing a major pharmaceutical company in an ANDA action involving challenges to patents covering the crystalline form and processes for the manufacture of our client's blockbuster drug.
Counseling a major pharmaceutical company in response to allegations of patent infringement related to its therapeutic monoclonal antibody.
Representing an online content provider in data piracy claims arising from unauthorized access to its proprietary database.
Defending a leading contact lens manufacturer in nationwide class action litigation involving allegations of anticompetitive pricing.
Successfully defended major pharmaceutical company against tying and monopolization claims, resulting in grant of our client’s motion to dismiss.
General Commercial Litigation
Represented a foreign truck part company in a high-stakes and complex commercial dispute with a joint venture partner, ending in grant of summary judgment to our client on the central issue of liability.
Representing a foreign manufacturing company in contract dispute regarding supply agreement.
Representing intervenor community organizations defending rent control regulation amendments in Article 78 proceeding.
Represented indigent tenants in landlord-tenant matters through the Firm’s partnerships with Legal Services of the Hudson Valley and the pediatric unit of New York Metropolitan Hospital
- U.S. District Court, Southern and Eastern Districts of New York
- New York
"U.S., European Biosimilar Approval Activity in 2017," Bloomberg BNA Life Sciences Law & Industry Report (February 2018)
"Update on Biosimilar Approvals and Pending Applications in Europe and the U.S.," Bloomberg BNA Life Sciences Law & Industry Report (June 2017)
- "All Camps Agree: Memorable Biosimilar Names are a Must," Law360 (December 2015)